Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 13/20 | 0.50 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.39 |
| ▸ | ELOVL6 | Q9H5J4 | 2/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | CCR3 | P51677 | 1/20 | 0.36 |
| ▸ | BCL2 | P10415 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3751560 | 0.85 | STS (0.48) | STSCACNA1BELOVL6HRH1CCR3 | |
| SCHEMBL3742710 | 0.84 | STS (0.51) | STSELOVL6HRH1CCR3 | |
| SCHEMBL10060683 | 0.74 | CYP2D6 (0.38) | CACNA1BELANE | |
| SCHEMBL7849129 | 0.74 | CYP2D6 (0.38) | CACNA1BELANE | |
| SCHEMBL13078574 | 0.74 | ALDH1A1 (0.35) | — | |
| SCHEMBL13078575 | 0.73 | CTSL (0.46) | CACNA1B | |
| SCHEMBL13078576 | 0.73 | DPP4 (0.37) | CACNA1BELANE | |
| SCHEMBL8081003 | 0.73 | CACNA1B (0.38) | CACNA1B | |
| SCHEMBL13078813 | 0.72 | CTSK (0.34) | CACNA1BELANE | |
| SCHEMBL8092352 | 0.71 | MGLL (0.37) | CACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338450-B2 | Compounds as dipeptidyl peptidase IV (DPP IV) inhibitors | LUPIN LIMITED (IN) | 2012-12-25 | — | — | US | disclosed |
| US-20100291020-A1 | NOVEL COMPOUNDS AS DIPEPTIDYL PEPTIDASE IV (DPP IV) INHIBITORS | LUPIN LIMITED (IN) | 2010-11-18 | — | — | US | disclosed |
| WO-2009037719-A1 | NOVEL COMPOUNDS AS DIPEPTIDYL PEPTIDASE IV (DPP IV) INHIBITORS | LUPIN LIMITED (IN) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100291020-A1 | NOVEL COMPOUNDS AS DIPEPTIDYL PEPTIDASE IV (DPP IV) INHIBITORS | DPP4, DPP7, DPP3 | STS 2135/4885CACNA1B 3223/4885ELOVL6 1589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.